Procore stock price target raised to $90 from Goldman Sachs on stabilizing growth
Investing.com - Cantor Fitzgerald has maintained its Overweight rating and $55.00 price target on Xenon Pharmaceuticals (NASDAQ:XENE) following the company’s recent webinar on its Nav1.7 inhibitor program for pain management. This target represents a 38% upside from the current price of $39.78, aligning with the broader analyst consensus that shows a Strong Buy recommendation and an average upside potential of 34%.
The research firm expressed strong approval of Xenon’s presentation, describing it as "exemplary" in its discussion of the pain treatment program.
Cantor Fitzgerald highlighted particular interest in the program’s development, noting that pain represents a "massive needle mover" in terms of unmet medical needs, specifically for effective non-opioid treatment options that combine potency with tolerability.
The firm indicated that the Nav1.7 inhibitor program’s progression into clinical trials and advancement toward proof-of-concept studies represents a significant milestone for Xenon Pharmaceuticals .
According to Cantor Fitzgerald, this specific asset could transform Xenon into what it terms a "can’t-miss" biopharma investment opportunity as development continues. InvestingPro analysis suggests Xenon is currently undervalued, with the company showing strong returns over the last three months, five years, and decade despite its current profitability challenges. Discover 10+ additional InvestingPro Tips and comprehensive analysis in Xenon’s Pro Research Report, available with an InvestingPro subscription.
In other recent news, Xenon Pharmaceuticals Inc. reported its third-quarter earnings for 2025, revealing an earnings per share (EPS) of -1.15 USD, which met market expectations. The company has maintained a strong cash reserve, ensuring that its operations are funded through 2027. This financial stability supports Xenon Pharmaceuticals’ focus on advancing its late-stage clinical developments. Despite the earnings being in line with projections, the company’s stock experienced a minor decline in regular and after-hours trading. These developments highlight the company’s ongoing commitment to its clinical pipeline and financial health. There have been no recent reports of mergers or acquisitions involving Xenon Pharmaceuticals. Analyst firms have not provided any recent upgrades or downgrades for the company. Investors may find the company’s financial strategy and clinical focus noteworthy in light of these recent updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.